Implantica announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop™

Contributed by: PR Newswire

Tags

IMPLANTICA-CE-mark

More Like This

Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval

Implantica announces continuing progress in modular PMA application to FDA for RefluxStop™

Implantica submits U.S. FDA Premarket Approval (PMA) application for RefluxStop® (first module)

Implantica publishes Interim Report January - June 2024 (Q2)

Implantica announces RefluxStop™ pivotal 4-year study results published in the prestigious journal Surgical Endoscopy

Implantica announces another landmark real-world RefluxStop™ study demonstrating excellent outcomes published in a prestigious top-tier journal

Implantica publishes Interim Report January - March 2024 (Q1)

Implantica announces excellent data from an independent study of 158 RefluxStop™ patients from two centers in Germany - presented at the AUGIS meeting in UK